Prevention of hepatitis B virus-associated liver diseases by antiviral therapy (Q38793117)

6 September 2017

title

Prevention of hepatitis B virus-associated liver diseases by antiviral therapy (English)

1 reference

6 September 2017

1 reference

1 reference

Akinobu Tawada

1

1 reference

6 September 2017

Tatsuo Kanda

series ordinal

2

1 reference

6 September 2017

Fumio Imazeki

series ordinal

3

1 reference

6 September 2017

Osamu Yokosuka

series ordinal

4

1 reference

6 September 2017

publication date

29 March 2016

1 reference

6 September 2017

published in

Hepatology international

1 reference

6 September 2017

volume

10

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

574-593

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta‐analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Entecavir in decompensated HBV cirrhosis: the future is looking brighter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Lamivudine treatment for acute severe hepatitis B: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

The study of efficacy of lamivudine in patients with severe acute hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Lamivudine treatment improves the prognosis of fulminant hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Entecavir to treat severe acute hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Clinical features of acute viral hepatitis B in Korea: a multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Hepatitis B virus infection among children born in the United States to Southeast Asian refugees

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Treatment of chronic hepatitis B: case selection and duration of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Combination treatment in HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9720-Y

Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha.

21 January 2018

1 reference

12 December 2020

To treat or not to treat? The judicious use of interferon-alpha-2a for the treatment of chronic hepatitis B

1 reference

12 December 2020

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma

1 reference

12 December 2020

The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma

1 reference

12 December 2020

Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group

1 reference

12 December 2020

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

1 reference

12 December 2020

Tenofovir Improves the Outcome in Patients with Spontaneous Reactivation of Hepatitis B Presenting as Acute-On-Chronic Liver Failure §Δ

1 reference

12 December 2020

Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma

1 reference

12 December 2020

Hepatitis B infection in Eastern Indian families: need for screening of adult siblings and mothers of adult index cases

1 reference

12 December 2020

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

12 December 2020

Recombinant interferon‐α therapy for acute hepatitis B: a randomized, double‐blind, placebo‐controlled trial

1 reference

12 December 2020

A randomized controlled trial of lamivudine to treat acute hepatitis B

1 reference

12 December 2020

Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosis

1 reference

12 December 2020

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

1 reference

12 December 2020

Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees

1 reference

12 December 2020

Hepatitis B antigen and antibody. Occurrence in families of asymptomatic HB AG carriers

1 reference

12 December 2020

Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B

1 reference

12 December 2020

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Gr

1 reference

12 December 2020

Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana

1 reference

12 December 2020

Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection

1 reference

12 December 2020

Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort

1 reference

12 December 2020

Interferon-alpha in the treatment of acute prolonged hepatitis B virus infection

1 reference

12 December 2020

Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial

1 reference

12 December 2020

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

12 December 2020

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

12 December 2020

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

12 December 2020

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection

1 reference

12 December 2020

Clinical Outcomes of Lamivudine-Adefovir Therapy in Chronic Hepatitis B Cirrhosis

1 reference

12 December 2020

10.1007/S12072-016-9720-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1047478134

0 references

1 reference